Table 1.

FDA approved checkpoint inhibitors targeting the programmed death or cytotoxic T lymphocyte antigen-4 pathways.

Drug and trade name	Target	FDA approval
Prembrolizumab KEYTRUDA	PD-1	Advanced melanoma PDL-1-positive metastatic non-small cell lung cancer Advanced or metastatic urothelial carcinoma Refractory classical Hodgkin’s lymphoma Recurrent or metastatic head and neck squamous cell carcinoma
Nivolumab OPDIVO	PD-1	Metastatic melanoma Locally advanced or metastatic urothelial carcinoma PDL-1+ non-small cell lung cancer (NSCLC)
Avelumab BAVENICO	PDL-1	Metastatic merkel cell carcinoma
Durvalumab IMFINZI	PDL-1	Metastatic bladder cancer
Atezolizumab TECENTRIQ	PDL-1	Locally advanced or metastatic urothelial carcinoma, PDL-1+ NSCLC
Ipilimumab YERVOY	Cytotoxic T-lymphocyte antigen 4	Metastatic melanoma